85 terminated. 85 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 85 | Terminated 85 |
| Phase 2 | 12 | Terminated 12 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Gilead Sciences | 378 | 2022-07-07 | 2025-04-04 |
| Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML Entospletinib, Placebo, Cytarabine - Nucleophosmin 1-mutated Acute Myeloid Leukemia | Phase 3 | Terminated | Kronos Bio | 15 | 2021-11-24 | 2024-01-10 |
| Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML Uproleselan, Placebo - Relapsed/Refractory AML | Phase 3 | Terminated | Apollomics Inc. | 140 | 2021-11-17 | 2025-06-27 |
| SPARK-ALL: Calaspargase Pegol in Adults With ALL Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Institut de Recherches Internationales Servier | 42 | 2021-07-07 | 2026-10-29 |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Gilead Sciences | 258 | 2021-07-01 | 2025-02-05 |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia Dociparstat, Control - Acute Myeloid Leukemia | Phase 3 | Terminated | Jazz Pharmaceuticals | 9 | 2021-04-30 | 2024-04-15 |
| Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib - Acute Myeloid Leukemia | Phase 3 | Terminated | University Hospital Heidelberg | 28 | 2021-04-01 | 2022-07-01 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Sabatolimab, Azacitidine, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Terminated | Novartis Pharmaceuticals | 530 | 2020-06-08 | 2026-01-13 |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) Venetoclax, Azacitidine, Best Supportive Care (BSC) - Acute Myeloid Leukemia (AML), Cancer | Phase 3 | Terminated | AbbVie | 465 | 2020-02-26 | 2026-06-04 |
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia Dexamethasone, Amsacrine, Cytarabine - Relapsed or Refractory Acute Myeloid Leukemia | Phase 3 | Terminated | University Hospital, Toulouse | 73 | 2020-01-13 | 2025-04-10 |
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality Optimal medical treatment, usual clinical practice - Chronic Myeloid Leukemia (CML) | Phase 3 | Terminated | University Hospital, Angers | 80 | 2019-12-20 | 2025-03-17 |
| Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage DFP-10917, Cytarabine, Azacitidine - Leukemia, Myeloid, Acute | Phase 3 | Terminated | Delta-Fly Pharma, Inc. | 167 | 2019-11-22 | 2026-01-22 |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) Ublituximab, Umbralisib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 / Phase 3 | Terminated | TG Therapeutics, Inc. | 277 | 2019-05-16 | 2024-04-19 |
| Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS rivogenlecleucel, rimiducid, Cyclophosphamide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Terminated | Bellicum Pharmaceuticals | 1 | 2018-12-27 | 2023-09-29 |
| Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia | Phase 3 | Terminated | Cornerstone Pharmaceuticals | 200 | 2018-11-12 | 2023-02-08 |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Uproleselan, Placebo - Acute Myeloid Leukemia | Phase 3 | Terminated | GlycoMimetics Incorporated | 388 | 2018-10-15 | 2024-07-29 |
| Panobinostat Maintenance After HSCT fo High-risk AML and MDS Panobinostat - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Terminated | Goethe University | 52 | 2018-07-24 | 2023-02-16 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
Showing 20 of 85. Sign in to see all of them.
Leukemia, Myeloid, Acute (34) · Leukemia, Lymphocytic, Chronic, B-Cell (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (15) · Myelodysplastic Syndromes (14) · Lymphoma (10) · Leukemia, Myeloid, Chronic-Phase (9) · Lymphoma, Follicular (8) · Lymphoma, B-Cell, Marginal Zone (7) · Myeloproliferative Disorders (7) · Leukemia, Myeloid (6) · Graft vs Host Disease (5) · Leukemia, Myelomonocytic, Chronic (5) · Lymphoma, Large B-Cell, Diffuse (5)
Hemic and Lymphatic Diseases (85) · Neoplasms by Histologic Type (83) · Hematologic Diseases (82) · Neoplasms (80) · Leukemia, Myeloid (48) · Disease Attributes (40) · Pathologic Processes (40) · Pathological Conditions, Signs and Symptoms (40) · Immune System Diseases (38) · Immunoproliferative Disorders (38) · Lymphatic Diseases (38) · Lymphoproliferative Disorders (38) · Chronic Disease (37) · Leukemia, Lymphoid (35)
Cytarabine (11) · Cyclophosphamide (10) · Azacitidine (8) · Imatinib Mesylate (7) · Etoposide (6) · fludarabine (6) · idelalisib (6) · nilotinib (6) · Busulfan (5) · Methotrexate (5) · Whole-Body Irradiation (5) · venetoclax (5) · Mitoxantrone (4) · Rituximab (4) · Bendamustine Hydrochloride (3)
Gilead Sciences (8) · Novartis Pharmaceuticals (7) · M.D. Anderson Cancer Center (3) · TG Therapeutics, Inc. (3) · Alliance for Clinical Trials in Oncology (2) · Ariad Pharmaceuticals (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Kiadis Pharma (2) · Masonic Cancer Center, University of Minnesota (2) · Merck Sharp & Dohme LLC (2) · University Hospital Carl Gustav Carus (2) · AbbVie (1) · Acute Leukemia French Association (1) · Amgen (1) · Apollomics Inc. (1)
United States (56) · France (27) · Germany (27) · Canada (24) · Italy (24) · Spain (24) · Australia (23) · United Kingdom (21) · Belgium (20) · Poland (16) · South Korea (15) · Czechia (14) · Israel (13) · Netherlands (13) · Austria (10)
Andrea Velardi, MD (1) · Benjamin Lichtiger, MD (1) · Ching-Hon Pui, MD (1) · Dan DeAngelo, MD (1) · Daniel J DeAngelo, MD, PhD (1)
PMID 37703506, PMID 15226337, PMID 15247354, PMID 18838471, PMID 19270260, PMID 20850381, PMID 21459791, PMID 22315495, PMID 22658895, PMID 22959335, PMID 23248249, PMID 23515925, PMID 23749683, PMID 24472814, PMID 24859364, PMID 25103870, PMID 25882396, PMID 27083332, PMID 28257752, PMID 28380315, PMID 29550384, PMID 30916608, PMID 30995176, PMID 32167393, PMID 32289160, PMID 32599655, PMID 33026184, PMID 33054084, PMID 33542479, PMID 33683917, PMID 34161631, PMID 34699069, PMID 34732236, PMID 35622074, PMID 36757706, PMID 37083373, PMID 40009500, PMID 40227676, PMID 40233321, PMID 40454396, PMID 41074700, PMID 41406403
2015 (3), U10CA031946 (2), 2008 (1), 2014 (1), 2016 (1), 2019 (1), 2023 (1), P30CA036727 (1), P30CA069533 (1), U01HL069294 (1), U24CA076518 (1)